Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 14, Issue 7, 2012, Pages 601-607

  Luippold, G ^a   Klein, T ^a   Mark, M ^a   Grempler, R ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

SGLT 2 inhibitor; Type 1 diabetes

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LINPLANT; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

EID: 84861886161     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01569.x     Document Type: Article

References (34)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
2. Achenbach P, Bonifacio E, Koczwara K, Ziegler A-G. Natural history of type 1 diabetes. Diabetes 2005; 54: S25-S31.
3. Garg SK, Voelmle MK, Beatson CR et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care 2011; 34: 574-579.
4. Schwab KO, Doerfer J, Hecker W et al. Spectrum and prevalence of atherogenic risk factors in 27 358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006; 29: 218-225.
5. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-1534.
6. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45: 937-948.
7. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912.
8. Feltbower RG, Bodansky HJ, Patterson CC et al. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire register of diabetes in children and young adults. Diabetes Care 2008; 31: 922-926.
9. Skrivarhaug T, Bangstad H-J, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006; 49: 298-305.
10. Larger E. Weight gain and insulin treatment. Diabetes Metab 2005; 31: 51-56.
11. Engström I, Kroon M, Arvidsson C-G, Segnestam K, Snellman K, Åman J. Eating disorders in adolescent girls with insulin-dependent diabetes mellitus: a population-based case-control study. Acta Paediatr 1999; 88: 175-180.
12. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551-559.
13. Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-1800.
14. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
15. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose costrasporter (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
16. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozinetabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008; 327: 268-276.
17. Fujimori Y, Katsuno K, Ojima K et al. Sergliflozinetabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009; 609: 148-154.
18. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozinetabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol 2009; 618: 98-104.
19. Yamamoto K, Uchida S, Kitano K et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol 2011; 164: 181-191.
20. Zhang W, Welihinda A, Mechanic J et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res 2011; 63: 284-293.
21. Thomas L, Grempler R, Eckhardt M et al. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab 2012; 14: 94-96.
22. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
23. Heise T, Seewaldt-Becker E, Macha S et al. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes 2010; 59: 629.
24. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971; 28: 101-109.
25. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int 2011; 79: S1-6.
26. Schneider S, Weber R, Luippold G. Blood glucose profiles in diabetic rodents using different insulin preparations. Arzneimittelforschung 2004; 54: 842-846.
27. +-glucose cotransporters. Am J Physiol 2001; 280: F10-F18.
28. Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22: 104-112.
29. Handlon AL. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents. Expert Opin Ther Pat 2005; 15: 1531-1540.
30. Ferrannini E. Learning from glycosuria. Diabetes 2011; 60: 695-696.
31. Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N, Sasso FC. Kidney in diabetes: from organ damage target to therapeutic target. Curr Drug Metab 2011; 12: 658-666.
32. Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 2009; 19: 1485-1499.
33. Grempler R, Thomas L, Klein T et al. Weight loss induced by potent and selective SGLT2 inhibitor, BI 10773, is due to body fat reduction. Studies in dietary-induced obese rats. Diabetes 2010; 59: 1793.
34. Nauck M, Del PS, Rohwedder K, Theuerkauf A, Langkilde AM, Parikh SJ. Long term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results. Diabetes Care 2011; 34: 2015.